Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — Patient history, growth rate and bleeding are important factors to consider when evaluating eyelid lesions and deciding whether or not to biopsy, according to a speaker.
“There are situations where we need to have heightened awareness. These skin cancers occur, and they can evolve,” Jeremiah Tao, MD, FACS, said during a presentation at Hawaiian Eye 2026.
“On examination, there are three key findings I think we should all be considering: Ulceration, irregularity and eyelid margin destruction. These are three features that should prompt you to put these patients into the